Global Recombinant Vaccines Market Report and Forecast 2025-2034

Global Recombinant Vaccines Market Outlook

The value of the global recombinant vaccine market was USD 14.91 billion in 2024, driven by the technological advancements in vaccine development across the globe. The market value is expected to grow at a CAGR of 11.9% during the forecast period of 2025-2034 to reach a value of USD 41.04 billion by 2034.

Key Trends in the Market

Recombinant vaccines are vaccines made with DNA recombination, primarily based on yeast or bacterial cells that are embedded into the host cell to trigger an immune response. Some examples of recombinant vaccines are vaccines against meningitis, hepatitis B, and Influenza B diseases. Recombinant vaccines are less risky, can be produced easily and are also capable of being inserted into multiple carriers. 

• Rapid increase in the number of people affected by the zoonotic diseases such as plague, rabies, zoonotic influenza, among other diseases, is expected to increase the demand for recombinant vaccines, fuelling the market growth.

• Key players have been constantly carrying out research and developments for recombinant vaccines with improved protective abilities which is expected to help in the growth of the market.

• Reduced hospital expenditure and reduced side effects of using the recombinant vaccines in comparison to other vaccines has increased its use and demand contributing to the growth of the recombinant vaccines market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

Based on type, the market can be bifurcated into live attenuated and subunit. By disease indication, the market is divided into hepatitis B, rotavirus, herpes zoster, and meningococcal B, among others. On the basis of end use, the market is segmented into paediatrics, adults, and veterinary. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global recombinant vaccines market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.

• GSK plc

• Pfizer Inc.

• Sanofi

• Walvax Biotechnology Co., Ltd. (Walvax)

• Dynavax Technologies Corporation

• Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Share by Type

Subunit types of recombinant vaccines are expected to hold a substantial share in the recombinant vaccines market because it does not contain whole virus or bacteria. Containing specific antigens helps these vaccines focus on a small number of antigens. It might require the person to take repeated doses but is considered safer to use in comparison to live attenuated vaccine. 

Live attenuated recombinant vaccines contain weakened forms of the virus they protect against. Although they provide long-lasting effects, they may not be suitable for people with weak immune systems. In people with weak immune systems, live attenuated recombinant vaccines risk causing the disease. 

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Market Share by End Use

Adult end users are a leading shareholder in the recombinant vaccines market because of increasing number of adult patients that are proactively protecting themselves from infectious diseases. This has increased the demand for recombinant vaccine to protect against diseases other vaccine do not prevent, thereby increasing its production. Due to the strong nature of recombinant vaccines, it is safer to give them to adults that can monitor and report any side effects, and have relatively stronger immune systems as compared to children. With new recombinant vaccines released, adults have a wider option to choose from. 

Competitive Landscape

GSK plc is pharmaceutical and biotechnology company that has its headquarter in Brentford, United Kingdom. It was founded in 2000 and manufactures specialty medicines along with innovative vaccines for the prevention and treatment of diseases. 

Pfizer Inc. founded in 1849 is headquartered in New York, United States. It is a specialised biotechnology and pharmaceutical company that develop and sell vaccines, medical devices, medicines, and healthcare products for treating diseases.

Sanofi was established in 2004 and is based out of Paris, France. A pharmaceutical and healthcare company, it aims to fulfil the health needs of people. They manufacture and sell various health products including vaccines and medicines. 

Other market players include Walvax Biotechnology Co., Ltd. (Walvax), and Dynavax Technologies Corporation, among others.

Key Highlights of the Report